647020-71-1

Basic information

• Product Name: methyl 2-bromo-3-fluorobenzoate
• Synonyms: methyl 2-bromo-3-fluorobenzoate
• CAS NO: 647020-71-1
• Molecular Formula: C₈H₆BrFO₂
• Molecular Weight: 233.0344432
• Mol File: 647020-71-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 248.8°C at 760 mmHg
• Flash Point: 104.3°C
• Appearance: /
• Density: 1.577g/cm³
• Vapor Pressure: 0.0237mmHg at 25°C
• Refractive Index: 1.531
• CAS DataBase Reference: methyl 2-bromo-3-fluorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-bromo-3-fluorobenzoate(647020-71-1)
• EPA Substance Registry System: methyl 2-bromo-3-fluorobenzoate(647020-71-1)

Safety Data

• Hazardous Substances Data: 647020-71-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H6BrFO2/c1-12-8(11)5-3-2-4-6(10)7(5)9/h2-4H,1H3

Upstream product

• 186581-53-3 diazomethane 
• 132715-69-6 2-bromo-3-fluoro-benzoic acid 
• 67-56-1 methanol 
• 851368-08-6 1-bromo-2-fluoro-6-iodobenzene 
• 1121-86-4 1-Fluoro-3-iodobenzene 

Downstream Products

• 1402838-29-2 methyl 3-fluoro-2-(1-trityl-1H-imidazol-4-yl)benzoate 
• 1402838-31-6 3-fluoro-2-(1-trityl-1H-imidazol-4-yl)benzaldehyde 
• 52045-42-8 4-fluoro-2-methyl-2,3-dihydro-1H-inden-1-one 

Relevant articles and documents

COMPOUNDS

This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prevention of diseases

Rh-Catalyzed Asymmetric Hydrogenation of α,β- and β,β-Disubstituted Unsaturated Boronate Esters

A highly enantioselective hydrogenation of α,β-unsaturated boronate esters catalyzed by Rh-(S)-DTBM-Segphos complex has been developed. Both (Z)-α,β- and β,β-disubstituted substrates can be successfully hydrogenated to afford chiral boronates with excellent enantioselectivities, up to 98 % ee. Furthermore, the obtained chiral boronate esters, as important versatile synthetic intermediates are successfully transformed to the corresponding chiral alcohols, amines and other important derivatives with maintained enantioselectivities.

ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS

The invention provides compounds of formula (I) pharmaceutically acceptable salt or solvate thereof, in which R1, A1, m and A are as defined in the specification; a process for their preparation; pharmaceutical compositions containin